Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines
ContributorsKoskinas, Konstantinos C; Gencer, Baris; Nanchen, David; Branca, Mattia; Carballo, David Andrés; Klingenberg, Roland; Blum, Manuel R; Carballo, Juan Sebastian; Muller, Olivier; Matter, Christian M; Lüscher, Thomas F; Rodondi, Nicolas; Heg, Dik; Wilhelm, Matthias; Räber, Lorenz; Mach, François; Windecker, Stephan
Published inEuropean journal of preventive cardiology, vol. 28, no. 1, p. 59-65
Publication date2021-03-23
First online date2020-07-20
Abstract
Keywords
- Lipids
- PCSK9 inhibitors
- Ezetimibe
- Secondary prevention
- Statins
- Atherosclerosis
- Cardiology
- Cardiovascular Diseases
- Europe
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
- PCSK9 Inhibitors / therapeutic use
- Practice Guidelines as Topic
- Proprotein Convertase 9
- Prospective Studies
- Societies, Medical
- United States
Affiliation entities
Research groups
Funding
Citation (ISO format)
KOSKINAS, Konstantinos C et al. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. In: European journal of preventive cardiology, 2021, vol. 28, n° 1, p. 59–65. doi: 10.1177/2047487320940102
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
- PID : unige:164691
- DOI : 10.1177/2047487320940102
- PMID : 33755142
Commercial URLhttps://academic.oup.com/eurjpc/article/28/1/59/6181741
Journal ISSN2047-4873